Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latanoprostene bunod - Bausch & Lomb

Next Previous
X
Search
Drug Profile

Latanoprostene bunod - Bausch & Lomb

Alternative Names: BOL-303259-X; CLIROPTA; NCX-116; PF-03187207; PF-3187207; Vesneo; VYZULTA

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Developer Bausch & Lomb
  • Class Antiglaucomas; Eye disorder therapies; Nitro compounds; Prostaglandins; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 31 Jan 2024 Nicox has a patent protection for the use of latanoprostene bunod for treatment of normal tension glaucoma, is eligible for five-year patent term extension in USA
  • 31 Jan 2024 Nicox, in collaboration with Bausch + Lomb seek patent term extension for the use of latanoprostene bunod for treatment of normal tension glaucoma in USA
  • 16 Sep 2022 NicOx intends to launch latanoprostene bunod for reduction of IOP in patients with open-angle glaucoma or ocular hypertension in Brazil in the fourth quarter of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top